Liposomal irinotecan combo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of liposomal irinotecan and albumin-bound paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line chemotherapy. It may be an option if you have already tried a fluorouracil-based treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have advanced stomach cancer or gastroesophageal junction cancer that cannot be removed by surgery.
- Your cancer has gotten worse after your first chemotherapy treatment that included fluorouracil.
- You have at least one tumor that can be measured by scans.
- Your blood counts and organ function levels need to be within certain limits.
- If you had HER2-positive cancer, you must have already received trastuzumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (adebrelimab, apatinib, and liposomal irinotecan) for people with advanced gastric or gastroesophageal junction cancer whose first treatment stopped working. The goal is to see if this new combination can help when standard options have failed.
This trial tests a new combination therapy using liposomal irinotecan for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line treatment. It may be an option if you are looking for a second-line therapy.
This trial tests a combination of two drugs – a new form of irinotecan (liposomal irinotecan) and an immunotherapy drug called sintilimab – for people with stomach cancer that has progressed after initial treatment. The goal is to see if this combination can work as a second-line option.
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
This trial tests a combination of three drugs (adebrelimab, famitinib, and irinotecan) for people with advanced stomach or gastroesophageal junction cancer that got worse after first-line treatment. It may offer a new option if you have already tried standard therapy.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.